| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3457 | Mp1104 | Novel mixed kappa-delta opioid receptor agonist with anti-cocaine properties and reduced side-effects in rats |
|
| DCC3458 | Mpges-1 Inhibitor-2 | Novel potent and selective microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor |
|
| DCC3459 | mpi621 | Novel anti-cancer agent, being more potent and safer than conventional indomethacin |
|
| DCC3460 | Mpk576 | Novel selective class IIb histone deacetylase inhibitor (HDACi), dose-dependently decreasing the viability of Acanthamoeba trophozoites |
|
| DCC3461 | Mpo-0029 | Potent and selective COX-2 inhibitor |
|
| DCC3462 | Mpp Dihydrochloride | Specific estrogen receptor α (ERα) antagonist |
|
| DCC3463 | Mpro-in-n3 | Novel main protease (Mpro) inhibitor, inhibiting MHV-A29, HCoV-229E, FOPV replication, and SARS-CoV-2 viral cell entry |
|
| DCC3464 | mps1 Inhibitor I | Novel Mps1 Kinase Inhibitor |
|
| DCC3465 | Mps-bay2b | Novel inhibitor of MPS1 |
|
| DCC3466 | Mpt0b206 | Novel tubulin polymerization inhibitor |
|
| DCC3467 | Mpt0b451 | Novel Dual HDAC6 and Tubulin Inhibitor, Displaying Anti-tumor Ability in Human Cancer Cells |
|
| DCC3468 | Mptp-in-22 | Novel mitochondrial permeability transition pore (mPTP) inhibitor |
|
| DCC3469 | Mpx-007 | Novel potent and selective antagonist of GluN2A-containing NMDA receptors |
|
| DCC3470 | Mq02-439 | Novel highly potent and selective 5-HT2C agonist |
|
| DCC3471 | Mr22388 | Novel, potent inducer of apoptosis via the MAP kinase pathways. Inhibitor of several kinases including the tyrosine kinase FLT3-ITD |
|
| DCC3472 | Mr6-31-2 | Novel inhibitor of the main protease (Mpro) of SARS-CoV-2 |
|
| DCC3473 | Mrgprx1 Pam 1t | Novel positive allosteric modulator (PAM) of mas-related G protein-coupled receptor X1 (MRGPRX1), reducing behavioral heat hypersensitivity in humanized MRGPRX1 mice, demonstrating the therapeutic potential in treating neuropathic pain |
|
| DCC3474 | Mrgx1-activator-1 | Activator of MrgX1 receptor signaling |
|
| DCC3475 | Mri-1891 | Novel peripheral CB1R antagonist, being highly biased toward inhibiting CB1R-induced β-arrestin-2 (βArr2) recruitment over G-protein activation |
|
| DCC3476 | Mrl-248 | Novel potent and selective RORγT inhibitor, showing no appreciable activity against a panel of related nuclear hormone receptors |
|
| DCC3477 | Mrl-299 | Novel potent RORγT inhibitor |
|
| DCC3478 | Mrl-367 | Novel potent and selective RORγT inhibitor, showing no appreciable activity against a panel of related nuclear hormone receptors |
|
| DCC3479 | Mrl-770 | Novel selective and reproducible inhibitor of DNA synthesis in E. coli JL553 |
|
| DCC3480 | Mrs2220 | Selective enhancer of the ATP effects at fast desensitizing P2X (P2X1 and P2X3) receptors |
|
| DCC3481 | mrs2690 | Potent P2Y14 receptor agonist |
|
| DCC3482 | mrs2693 Trisodium | Selective P2Y6 agonist |
|
| DCC3483 | mrs2768 | Selective P2Y2 agonist |
|
| DCC3484 | mrs2957 | Potent P2Y6 agonist |
|
| DCC3485 | Mrs2964 | Potent and selective P2Y6 receptor agonist |
|
| DCC3486 | Mrs4598 | Novel highly potent human CD73 inhibitor (K i = 0.673 nM) |
|
